2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5875 Transcriptional regulation of CD19 by IKZF1 enhances CAR T-cell immune targeting in mantle cell lymphoma

Anya Sondhi, BS, BA, Tulasigeri Totiger2, Stanzin Idga3, Hari Kumar Arigela4, Abdessamad Youssfi Alaoui, PhD5, Genevieve Driscoll6, Chris Armstrong7, Jonathan Harry Schatz, MD8, Jay Y Spiegel, MD9, Justin Taylor, MD10
1 University of Miami, Miami, Florida, United States
2 University of Miami, Miami, Florida, United States
3 University of Miami, Miami, Florida, United States
4 University of Miami, Miami, Florida, United States
5 University of Miami, Miami, Florida, United States
6 University of Miami, Miami, Florida, United States
7 University of Miami, Miami, Florida, United States
8 University of Miami, Miami, Florida, United States
9 University of Miami, Miami, Florida, United States
10 University of Miami, Miami, Florida, United States

Background: CD19-directed chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory mantle cell lymphoma (MCL), yet most patients ultimately relapse because of antigen escape (reduced CD19 surface expression). CD19 antigen density is a critical determinant of CAR T-cell activation and cytotoxicity, but the transcriptional mechanisms regulating CD19 expression remain poorly understood. IKZF1 is a master regulator transcription factor whose activity is negatively regulated by casein kinase 2α (CK2α). We hypothesized that genetic or pharmacologic activation of IKZF1 would increase CD19 antigen density, thereby enhancing CAR T-cell recognition and antitumor activity.

Methods: Human MCL cell lines (JeKo-1 and Mino) and ALL (Nalm-6) cells were engineered to overexpress IKZF1 by lentiviral transduction alongside parental and empty-vector controls. Endogenous IKZF1 activity was pharmacologically enhanced using the CK2α inhibitor silmitasertib. CD19 transcript abundance, promoter activity, and quantitative surface expression were assessed by RT-qPCR, luciferase reporter assays, and calibrated bead-based flow cytometry. Tumor cells were co-cultured with CD19-directed CAR T cells across multiple effector-to-target ratios, with cytotoxicity measured by LDH release and viability assays. CAR T-cell activation was evaluated using multiplex cytokine profiling, and differential chromatin binding analyses were performed to define IKZF1-dependent transcriptional remodeling. A luciferase-expressing mantle cell lymphoma xenograft model was generated to evaluate IKZF1 overexpression efficacy of CD19 CAR-T-cell efficacy in vivo. Following tumor engraftment, mice bearing wild-type or IKZF1-overexpressing JeKo-1 tumors receive vehicle or CD19 CAR-T cells and undergo longitudinal bioluminescence imaging to assess tumor burden and overall survival. Circulating cytokines, CAR-T-cell persistence, and residual disease in peripheral blood, spleen, bone marrow, and liver will be analyzed to determine whether IKZF1-mediated upregulation of surface CD19 improves CAR-T-cell activity and durability.

 

Results: IKZF1 overexpression significantly increased CD19 transcript and cell surface expression across MCL models, producing approximately 2.5-fold increases in JeKo-1 cells and 2.3-fold increases in Mino cells. Pharmacologic CK2α inhibition with silmitasertib closely phenocopied these effects, supporting CK2α as an upstream negative regulator of IKZF1-mediated CD19 expression. Increased antigen density translated directly into enhanced CAR T-cell function. CAR T-cell-mediated cytotoxicity increased from approximately 60% against parental and empty-vector controls to approximately 80% against IKZF1-overexpressing targets across multiple effector-to-target ratios. Importantly, blockade of CD19 with tafasitamab completely abolished the enhanced cytotoxicity, whereas isotype controls had no effect, demonstrating that improved tumor cell killing resulted specifically from increased CD19 antigen availability. Consistent with enhanced CAR T-cell activation, multiplex cytokine profiling demonstrated marked increases in IFNγ, IL-2, TNF, granzyme B, perforin, and inflammatory chemokines in co-cultures containing IKZF1-overexpressing or silmitasertib-treated tumor cells. Unsupervised clustering identified a distinct immune activation signature compared with tumor-only and CAR T-only controls. Differential chromatin binding analyses further demonstrated widespread IKZF1-dependent remodeling of regulatory elements consistent with enhanced antigen expression and immune recognition. Ongoing studies evaluate whether IKZF1 overexpression enhances CD19 CAR-T-cell efficacy in vivo.

Conclusions: CD19 antigen density is a key determinant of CAR T-cell efficacy in mantle cell lymphoma and is regulated by the CK2α–IKZF1 signaling axis. Pharmacologic CK2α inhibition increases CD19 expression, enhances CAR T-cell activation and cytotoxicity, and overcomes antigen-limited immune responses. These findings identify the CK2α–IKZF1 axis as a therapeutically actionable mechanism for augmenting CD19-directed CAR T-cell therapy and provide a strong preclinical rationale for combining CK2α inhibition with CAR T-cell therapy to improve the depth and durability of responses in mantle cell lymphoma.

Anya Sondhi, BS, BA: No relevant conflicts of interest to declare.